News Blog Archive
The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
Wang awarded NCI grant to study tumor recurrence after radiation therapy
Xiang-Yang (Shawn) Wang, Ph.D., was recently awarded a $316,438 grant from the National Cancer Institute (NCI) to support his studies of tumor recurrence after radiation therapy (RT). The grant was funded after a Massey pilot project discovered preliminary data that established a previously unrecognized feature of an innate receptor in host-tumor interaction during radiotherapy.
Arthur awarded endowed chair
Douglas Arthur, MD, associate director for clinical affairs and vice chair of the Department of Radiation Oncology, has been awarded the Natalie N. and John R. Congdon, Sr. Endowed Chair in Cancer Research, in recognition of his significant, ongoing contributions to VCU Massey Cancer Center’s research mission.
Holding the promise to improved health care
Electronic health records (EHRs) hold the promise to improve primary health care for millions of patients. However, enhancing current EHR functionality is needed to better support primary care clinicians and patients, according to a recent article.
Newly discovered signaling pathway could impact a variety of autoinflammatory diseases
Researchers from Massey have discovered a new signaling pathway in sterile inflammation that could impact the treatment of diseases such as cancer, multiple sclerosis and rheumatoid arthritis. Their findings offer insight into the role that activation of interferon-regulatory factor 1 (IRF1), a protein that functions as a transcriptional activator of a variety of target genes, plays in the production of chemokines and the recruitment of mononuclear cells to sites of sterile inflammation.
VCU Massey researcher works to develop new cancer-fighting drugs and target therapies
Matthew Hartman, Ph.D., has focused his research on two hot topics in the arena of cancer research: developing drugs that inhibit key cancer proteins and developing better ways to target cancer tumors. He studies how proteins interact with each other on the molecular level.